Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates /631/326/596 /692/699/255/1901 /82/58 /38/91 /82/80 articleScientific Reports.  8. 2018
2018 Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaquesJournal of Lipid Research.  59:2075-2083. 2018
2018 Development of a repeat-exposure penile SHIV infection model in macaques to evaluate biomedical preventions against HIVPLoS ONE.  13. 2018
2018 ApoA-I Mimetic Peptide 4F Reduces Age-Related Lipid Deposition in Murine Bruch’s Membrane and Causes Its Structural RemodelingCurrent Eye Research.  43:135-146. 2018
2018 The apolipoprotein e mimetic peptide AEM-2 attenuates mitochondrial injury and apoptosis in human THP-1 macrophagesCurrent topics in peptide & protein research.  19:15-25. 2018
2016 Apolipoprotein mimetic peptides as modulators of lipoprotein functionProtein and Peptide Letters.  23:1024-1031. 2016
2015 Analysis of putative mucosal SHIV susceptibility factors during repeated DMPA treatments in pigtail macaquesJournal of Medical Primatology.  44:286-295. 2015
2015 Rectal application of a highly osmolar personal lubricant in a macaque model induces acute cytotoxicity but does not increase risk of SHIV infectionPLoS ONE.  10. 2015
2014 Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: A reviewJournal of Lipid Research.  55:2007-2021. 2014
2014 Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18AInnate Immunity.  20:867-880. 2014
2014 Evaluation of pigtail macaques as a model for the effects of copper intrauterine devices on HIV infectionJournal of Medical Primatology.  43:349-359. 2014
2014 Pharmacokinetic and safety analyses of tenofovir and tenofovir- emtricitabine vaginal tablets in pigtailed macaquesAntimicrobial Agents and Chemotherapy.  58:2665-2674. 2014
2014 Preclinical evaluation of the immunomodulatory lymphocyte trafficking drug FTY720 for HIV prevention in the female genital mucosa of macaquesJournal of Medical Primatology.  43:370-373. 2014
2013 Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in ratsBiochemical and Biophysical Research Communications.  436:705-710. 2013
2013 Recent progress in the development of apoA-I and apoE mimetic therapiesFuture Lipidology.  8:265-268. 2013
2013 Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null miceAtherosclerosis.  227:58-64. 2013
2013 In vivo and in vitro effects of an apolipoprotein E mimetic peptide on amyloid-β pathologyJournal of Alzheimer's Disease.  36:335-347. 2013
2013 Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouseRedox Biology.  1:381-386. 2013
2012 Deletion of specific immune-modulatory genes from modified vaccinia virus ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaquesJournal of Virology.  86:12605-12615. 2012
2012 Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null miceAtherosclerosis.  224:326-331. 2012
2012 Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptidesJournal of Lipid Research.  53:849-858. 2012
2011 Apolipoprotein E mimetics and cholesterol-lowering propertiesAmerican Journal of Cardiovascular Drugs.  11:371-381. 2011
2011 Nucleosides accelerate inflammatory osteolysis, acting as distinct innate immune activatorsJournal of Bone and Mineral Research.  26:1913-1925. 2011
2011 Viral CTL escape mutants are generated in lymph nodes and subsequently become fixed in plasma and rectal mucosa during acute SIV infection of macaquesPLoS Pathogens.  7. 2011
2011 Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaquesMolecular Therapy.  19:417-426. 2011
2010 ApoE mimetic peptide reduces plasma lipid hydroperoxide content with a concomitant increase in HDL paraoxonase activityAdvances in Experimental Medicine and Biology.  660:1-4. 2010
2010 Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null miceJournal of Lipid Research.  51:3491-3499. 2010
2010 Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effectsAtherosclerosis.  213:449-457. 2010
2010 Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH2Atherosclerosis.  208:134-141. 2010
2009 Selective removal of stratum corneum by microdermabrasion to increase skin permeabilityEuropean Journal of Pharmaceutical Sciences.  38:95-103. 2009
2009 Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promotersJournal of Virology.  83:8182-8190. 2009
2009 Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progressionJournal of Immunology.  183:706-717. 2009
2009 Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's diseaseNeurobiology of Disease.  34:525-534. 2009
2009 Expanding the repertoire of modified vaccinia Ankara-based vaccine vectors via genetic complementation strategiesPLoS ONE.  4. 2009
2009 Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).Vascular Disease Prevention.  6:122-130. 2009
2008 HDL therapy for cardiovascular diseases: The road to HDL mimeticsCurrent Atherosclerosis Reports.  10:405-412. 2008
2007 Estimating the effectiveness of simian immunodeficiency virus-specific CD8+ T cells from the dynamics of viral immune escapeJournal of Virology.  81:11982-11991. 2007
2007 Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homingVirology.  367:156-167. 2007
2007 Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptidesJournal of Lipid Research.  48:1915-1923. 2007
2007 ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayersJournal of Biological Chemistry.  282:1980-1988. 2007
2006 Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virusJournal of Virology.  80:8469-8481. 2006
2006 Atherosclerosis and vascular disease: Effects of peptide mimetics of apolilpoproteinsCurrent Pharmaceutical Biotechnology.  7:235-240. 2006
2006 Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus Ankara enhances antiviral cellular and humoral immune responsesJournal of Virology.  80:7676-7687. 2006
2006 Potential clinical utility of high-density lipoprotein-mimetic peptidesCurrent Opinion in Lipidology.  17:440-444. 2006
2006 Synthetic peptides: Managing lipid disordersCurrent Opinion in Lipidology.  17:233-237. 2006
2006 Oral amphipathic peptides as therapeutic agentsExpert Opinion on Investigational Drugs.  15:13-21. 2006
2005 An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null miceArteriosclerosis, Thrombosis, and Vascular Biology.  25:1932-1937. 2005
2005 Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptideCirculation Research.  97:236-243. 2005
2005 Apolipoprotein A-I mimetic peptides - ATVB in focusArteriosclerosis, Thrombosis, and Vascular Biology.  25:1325-1331. 2005
2005 D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null miceArteriosclerosis, Thrombosis, and Vascular Biology.  25:1426-1432. 2005
2005 Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe heritable hyperlipidemic rabbitsCirculation.  111:3112-3118. 2005
2005 Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hostsJournal of Virology.  79:4043-4054. 2005
2004 Human apolipoprotein A-I and A-I mimetic peptides: Potential for atherosclerosis reversalCurrent Opinion in Lipidology.  15:645-649. 2004
2004 Prospects for an AIDS vaccine: Three big questions, no easy answersLancet Infectious Diseases.  4:397-413. 2004
2004 Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activityJournal of Biological Chemistry.  279:26509-26517. 2004
2004 Roles of Target Cells and Virus-Specific Cellular Immunity in Primary Simian Immunodeficiency Virus InfectionJournal of Virology.  78:4866-4875. 2004
2004 Blockade of T cell costimulation reveals interrelated actions of CD4 + and CD8+ T cells in control of SIV replicationJournal of Clinical Investigation.  113:836-845. 2004
2004 Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.Circulation.  109:3215-3220. 2004
2003 Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosisCurrent Opinion in Investigational Drugs.  4:1100-1104. 2003
2003 AIDS vaccine development: The long and winding roadAids Reviews.  5:131-139. 2003
2003 Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic miceAtherosclerosis.  168:229-237. 2003
2003 Association of Aortic Atherosclerosis with Cerebral β-Amyloidosis and Learning Deficits in a Mouse Model of Alzheimer's DiseaseAmerican Journal of Pathology.  163:2155-2164. 2003
2002 Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptideCirculation.  106:1127-1132. 2002
2002 Neither LAT nor open reading frame P mutations increase expression of spliced or intron-containing ICP0 transcripts in mouse ganglia latently infected with herpes simplex virusJournal of Virology.  76:4764-4772. 2002
2002 Sustained-delivery of an apolipoproteinE-peptidomimetic using multivesicular liposomes lowers serum cholesterol levelsJournal of Controlled Release.  79:207-218. 2002
2002 Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterolCirculation.  105:290-292. 2002
2001 Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptideJournal of Lipid Research.  42:1096-1104. 2001
2001 Toward the design of peptide mimics of antiatherogenic apolipoproteins A-I and ECurrent Science.  81:53-65. 2001
2001 Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivoJournal of Lipid Research.  42:959-966. 2001
2001 A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosisJournal of Lipid Research.  42:545-552. 2001
2000 Persistent elevated expression of cytokine transcripts in ganglia latently infected with herpes simplex virus in the absence of ganglionic replication or reactivationVirology.  278:207-216. 2000
2000 A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samplesJournal of Lipid Research.  41:1020-1026. 2000
2000 The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblastsBiochemistry.  39:213-220. 2000
1997 Quantification of HDL2 and HDL3 cholesterol by the vertical auto profile-II (VAP-II) methodologyJournal of Lipid Research.  38:2353-2364. 1997
1997 A LAT-associated function reduces productive-cycle gene expression during acute infection of murine sensory neurons with herpes simplex virus type 1Journal of Virology.  71:5885-5893. 1997
1997 The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humansClinical Science.  92:473-479. 1997
1996 Chromatographic methods for quantitation of apolipoprotein A-IMethods in Enzymology.  263:267-282. 1996
1995 A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterolArteriosclerosis, Thrombosis, and Vascular Biology.  15:2151-2156. 1995
1995 Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodologyJournal of Lipid Research.  36:2291-2302. 1995
1994 ApoB-100 has a pentapartite structure composed of three amphipathic α-helical domains alternating with two amphipathic β-strand domains: Detection by the computer program LOCATEArteriosclerosis, Thrombosis, and Vascular Biology.  14:1674-1685. 1994
1994 Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectorsJournal of Comparative Neurology.  339:3-11. 1994
1994 Gene transfer to sensory neurons using herpes virus vectors.Gene Therapy.  1 Suppl 1. 1994
1994 Quantification of cholesterol in all lipoprotein classes by the VAP-II methodJournal of Lipid Research.  35:159-168. 1994
1994 The amphipathic α helix: A multifunctional structural motif in plasma apolipoproteinsAdvances in Protein Chemistry.  45:303-369. 1994
1993 Cholesterol-lowering diets: Dealing with long-term adherence problemsCardiology Board Review.  10. 1993
1993 Demonstration of circularization of herpes simplex virus DNA following infection using pulsed field gel electrophoresisVirology.  197:459-462. 1993
1993 Thyroid function and other clinical chemistry parameters in subjects eating iodine-enriched eggsFood and Chemical Toxicology.  31:247-251. 1993
1992 Plasma lipoproteins in hyperlipidemic subjects eating iodine-enriched eggsJournal of the American College of Nutrition.  11:294-303. 1992
1992 Saturated fats, cholesterol, and dietary compliance.Archives of Internal Medicine -New Series-.  152:1167-1174. 1992
1992 Analysis for cholesterol in all lipoprotein classes by single vertical ultracentrifugation of fingerstick blood and controlled-dispersion flow analysisClinical Chemistry.  38:1898-1905. 1992
1992 Gene transfer into mammalian central nervous system using herpes virus vectors: Extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoterHuman Gene Therapy.  3:487-499. 1992
1992 Saturated Fats, Cholesterol, and Dietary ComplianceArchives of Internal Medicine -New Series-.  152:1167-1174. 1992
1992 Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats: Correlation with physical propertiesArteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association.  12:886-894. 1992
1988 Ascites fluid lipoproteins in experimental nephrotic syndromeBBA - Lipids and Lipid Metabolism.  959:253-261. 1988
1985 Lipoproteins of ascites fluid from nephrotic ratsFederation proceedings.  44:6112. 1985
1984 Catabolism of very low density lipoproteins in experimental nephrosisJournal of Clinical Investigation.  74:1375-1383. 1984

Research Overview

  • Coronary vascular disease, including heart disease and stroke, is the leading cause of death in the developed world. Numerous studies have shown that high levels of low density lipoprotein (LDL) cholesterol are associated with increased risk for atherosclerotic heart disease, while high levels of high density lipoprotein (HDL) are associated with reduced risk. The major protein component of HDL, apolipoprotein (apo) A-I, is considered to be primarily responsible for the atheroprotective properties of HDL. Apo E associates with chylomicrons, very low density lipoproteins (VLDL), and HDL, and mediates the clearance of triglyceride-rich lipoproteins. Both apo A-I and E have anti-inflammatory properties that contribute to atheroprotective properties.

    Our group has pioneered the design of peptide mimetics of apolipoproteins that have similar structural motifs as apo A-I and apo E, and has used these mimetic peptides to study the physical properties of apo A-I and apo E. My laboratory has extended these studies into animal models with the intent to use peptide mimetics of apolipoproteins to determine what properties of apo A-I and apo E prevent atherosclerosis and inflammatory processes in vivo. We are now extending these studies into animal models of Alzheimer ’s disease and insulin resistance.
  • Education And Training

    Full Name

  • David Garber